Market Overview

Amarin Receives FDA Notification That Action on ANCHOR sNDA Review Will be Delayed


Amarin (Nasdaq: AMRN) announced today that the U.S. Food and Drug Administration (FDA) notified the company last night that the FDA does not expect to take action on Amarin's supplemental new drug application (sNDA) for the proposed ANCHOR indication labeling expansion for Vascepa® (icosapent ethyl) capsules on the December 20, 2013 Prescription Drug User Fee Act (PDUFA) goal date because Amarin's request to re-instate the ANCHOR Special Protocol Assessment (SPA) agreement remains under consideration with the FDA. No new PDUFA date was established.

See full press release

Posted-In: News Contracts FDA Management Global


Related Articles (AMRN)

View Comments and Join the Discussion!

American Vanguard Says Elevated Channel Inventory will Affect Q4 and Full Year 2013 Performance

PeptiDream Announces Collaboration, License Agreement with Lilly